British Biosimilars Association launches in UK

New industry body the British Biosimilars Association (BBA) has officially launched in the UK.

The British Generic Manufacturers Association (BGMA) released a statement yesterday, April 18, where it outlined what the body’s core focus will be.

The BBA is an expert sector group of the BGMA and is focused on biosimilar medicines. Its  focus will be on ensuring patients can benefit from these medicines to the “same extent” as those in Europe.

According to the BGMA, the UK is currently lagging behind some European countries in the take-up of biosimilar medicines.

The BGMA also said that “restricting patient access to these medicines costs the National Health Service money” that could be used for other treatments.